in recently launched products and certain in-line products.

• Research and development expenses increased 31% in 2014 compared to 2013, reflecting incremental investment in late-stage pipeline products.

• The favorable change in Other (income)/deductions––net in 2014, compared to 2013, primarily reflects an increase in royalty-related income, primarily due to royalties earned on sales of Enbrel in the U.S. and Canada after October 31, 2013. As noted above, on that date, the co-promotion term of the collaboration agreement for Enbrel in the U.S. and Canada expired, and Pfizer became entitled to royalties for a 36-month period thereafter.

2013 vs. 2012:

• Revenues increased 4% to $14,317 million in 2013, compared to $13,756 million in the same period in 2012, primarily due to:

strong operational growth from Lyrica and Xeljanz in the U.S., and the launch in February 2013 of Eliquis. partially offset by:

the expiration of the co-promotion term of the collaboration agreement for Enbrel in the U.S. and Canada on October 31, 2013 (a decline of approximately $92 million in 2013); and

loss of exclusivity for Lyrica in Canada in February 2013 (a decline of approximately $104 million in 2013). Total GIP revenues from emerging markets were $1.6 billion in 2013.

• Cost of sales as a percentage of Revenues decreased 1% in 2013 compared to 2012, partially due to the favorable impact of foreign exchange plus a favorable shift in product mix partially offset by the unfavorable impact of the loss of Enbrel alliance revenues after October 31, 2013.

• Selling, informational and administrative expenses increased 14% in 2013 compared to 2012, reflecting increased investments in recently launched products and certain in-line products.

• Research and development expenses increased 12% in 2013 compared to 2012, reflecting investment in pipeline assets and additional indications for Xeljanz.

• The favorable change in Other (income)/deductions––net in 2013, compared to 2012, primarily reflects an increase in royalty-related income, primarily due to royalties earned on sales of Enbrel in the U.S. and Canada after October 31, 2013.

Global Vaccines, Oncology and Consumer Healthcare Operating Segment

2014 vs. 2013:

• Revenues increased 9% in 2014, compared to 2013, which includes an increase in operational revenues of 11% in 2014.

Global Vaccines Revenues increased 13% to $4,480 million in 2014, compared to $3,965 million in 2013, reflecting an increase in operational revenues of 15% in 2014. The increase was primarily due to the performance of Prevnar 13 in the U.S., primarily reflecting the timing of government purchasing patterns, increased prices and increased demand among adults following the positive recommendation from the U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices for use in adults aged 65 and over. International revenues for the Prevenar family increased 10% operationally in 2014, which primarily reflects increased shipments associated with the Global Alliance for Vaccines and Immunization (GAVI) as well as the timing of government purchases in various emerging markets compared with 2013.

Foreign